Assessment of Side Effects and Outcomes in Older Patients Receiving CAR-T or Bispecific Antibody Therapy Using Geriatric Evaluation

What this Trial Is About

Researchers are studying the effects of CAR-T cell and bispecific antibody therapies in older adults aged 65 and above who have aggressive types of lymphoma or plasma cell diseases like multiple myeloma. These treatments are new and intense, with potential serious side effects, but little is known about how older patients tolerate them or what the long-term impacts are. The study aims to use simple clinical methods to assess everyday functions important to older adults, such as mobility and memory, to better predict treatment risks and side effects. The study involves a pragmatic geriatric assessment before patients undergo CAR-T or bispecific antibody therapies. This assessment focuses on areas like mobility, self-care, nutrition, and cognitive function to evaluate patients fitness for these treatments. The goal is to see if these assessments can predict severe or lasting side effects and improve treatment planning for older patients. This observational study does not involve assigning specific treatments but monitors patients receiving these therapies as part of their care. During the study, participants will be evaluated from enrollment through three months after treatment ends for treatment toxicity and health-related quality of life. Researchers will use the assessments to monitor side effects and outcomes over time. The study also aims to develop a standardized screening process that could become routine before such therapies, potentially improving quality of life and reducing healthcare costs for older patients receiving these treatments.

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)